A phase 1 study of DS-8201a in combination with olaparib in HER2-expressing malignancies (CTEP #10355): Results of module 1 dose escalation

被引：0
|
作者：
Lee, Elizabeth K.
Hendrickson, Andrea E. Wahner
Colon-Otero, Gerardo
Pickett, Cheryl A.
Xiong, Niya
Cheng, Su-Chun
Polak, Madeline
Sawyer, Hannah
Hayes, Martin
Matulonis, Ursula A.
Shapiro, Geoffrey I.
Konstantinopoulos, Panagiotis A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B041
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies
    Fountzilas, Christos
    Javle, Milind
    Tan, Wei
    Ma, Yingyu
    Fetterly, Gerald
    Iyer, Renuka
    Johnson, Candace
    CANCER, 2018, 124 (19) : 3890 - 3899
  • [42] Phase 1 study of ZW25, a bispecific anti-HER2 antibody, in patients with advanced HER2-expressing cancers.
    Hausman, Diana Felice
    Hamilton, Erika Paige
    Beeram, Muralidhar
    Thimmarayappa, Jamuna
    Ng, Gordon
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [43] Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of GS-4059 in Combination with Idelalisib in Subjects with B-Cell Malignancies
    Salles, Gilles A.
    Morschhauser, Franck
    Cheson, Bruce
    Rule, Simon A.
    Fegan, Christopher
    Guillaume, Cartron
    Nelson, Cara
    Yang, Yingsi
    Mitra, Siddhartha
    Starodub, Alexander
    Dyer, Martin J. S.
    BLOOD, 2016, 128 (22)
  • [44] DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, abrogates the resistance to T-DM1 in HER2-positive gastric cancer: a preclinical study
    Nonagase, Yoshikane
    Takegawa, Naoki
    Yonesaka, Kimio
    Sakai, Kazuko
    Ogitani, Yusuke
    Tsurutani, Junji
    Nishio, Kazuto
    Nakagawa, Kazuhiko
    CANCER RESEARCH, 2017, 77
  • [45] PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF TRANSCON TLR7/8 AGONIST ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMOR MALIGNANCIES: INITIAL RESULTS FROM DOSE ESCALATION
    Davar, Diwakar
    Aghmesheh, Morteza
    Algazi, Alain
    Bajor, David
    Ganju, Vinod
    Laux, Douglas
    Spira, Alexander
    Ahern, Elizabeth
    Grewal, Jaspreet
    Rand, Jamie
    Sweis, Randy
    Karlsson, Jens-Jakob
    Kriegbaum, Mette
    Wu, Yang
    Tran, Tuan-Anh
    Singel, Stina
    Gabrail, Nashat
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A795 - A795
  • [46] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).
    Yoshino, Takayuki
    Di Bartolomeo, Maria
    Raghav, Kanwal Pratap Singh
    Masuishi, Toshiki
    Loupakis, Fotios
    Kawakami, Hisato
    Yamaguchi, Kensei
    Nishina, Tomohiro
    Wainberg, Zev A.
    Elez, Elena
    Rodriguez, Javier
    Fakih, Marwan
    Ciardiello, Fortunato
    Saxena, Kapil
    Kobayashi, Kojiro
    Bako, Emarjola
    Okuda, Yasuyuki
    Meinhardt, Gerold
    Grothey, Axel
    Siena, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [48] A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies
    Ku, G.
    Bendell, J. C.
    Tolcher, A. W.
    Hurvitz, S. A.
    Krishnamurthy, A.
    El-Khoueiry, A. B.
    Patnaik, A.
    Shroff, R. T.
    Noonan, A.
    Hahn, N. M.
    Matrana, M.
    Zettl, M.
    Aviano, K.
    Mar, L.
    Jolicoeur, P.
    Olwill, S.
    Bruns, I.
    Piha-Paul, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S462 - S463
  • [49] A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer
    Kim, Sung-Bae
    Ahn, Jin-Hee
    Kim, Jeongeun
    Jung, Kyung Hae
    MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT, 2015, 2 : 15031
  • [50] A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors
    Hurvitz, Sara A.
    Hamilton, Erika P.
    Spira, Alexander I.
    Pohlmann, Paula R.
    Giordano, Antonio
    Clifton, Katherine
    Anderson, Barry Douglas
    Dutta, Sujoy
    Mangipudi, Umesh
    Saini, Shikha
    Palacino, James
    Karunaratne, Tina
    Greensmith, Dennise
    Christensen, Olaf
    Wilks, Sharon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345